You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

AREXVY overview

Arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 60 years of age and older. Arexvy is administered as a single dose.

For further information please consult the patient information leaflet (PIL).

Summary of product characteristics

This link will take you to the electronic Medicines Compendium (eMC) website which is a non-GSK website.

View Summary of product of characteristics (GB)
View Summary of product of characteristics (NI)

Patient information leaflet

This link will take you to the electronic Medicines Compendium (eMC) website which is a non-GSK website.

View Patient information leaflet (GB)
View Patient information leaflet (NI)

▼ - This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the Patient information leaflet.

You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store.

By reporting side effects you can help provide more information on the safety of this medicine.

AREXVY is a registered trademark of the GlaxoSmithKline group of companies.